Emerging LNP Technology and mRNA Strategies for In Vivo CAR-T Development

This webinar will delve into the transformative role of mRNA and lipid nanoparticle (LNP) technology in driving advancements in in vivo CAR T-cell therapy.

We will begin by exploring the foundational principles of mRNA-based CAR T development, focusing on how mRNA enables transient yet precise expression of therapeutic CAR constructs. Additionally, we will discuss the critical role of LNPs in ensuring efficient and targeted delivery of mRNA to immune cells in vivo. The second half of the presentation will highlight how GenScript is supporting researchers in optimizing mRNA and LNP platforms for in vivo CAR T applications. From cutting-edge synthesis and tailored LNP formulations to robust analytical solutions, GenScript’s tools and services are designed to help overcome key challenges in this emerging therapeutic approach. Attendees will gain valuable insights into the latest innovations in mRNA and LNP technology and how they are shaping the future of CAR T-cell therapy.

Join our speaker to:

• Understand the fundamental principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development.
• Learn how GenScript’s tailored solutions, including mRNA synthesis, LNP formulation, and comprehensive analytical support, can help accelerate progress in this field.
• Discover the latest advancements in mRNA and LNP-based CAR T therapies and how they are paving the way for groundbreaking immuno-oncology treatments.

Speaker-related Webinars